PIR International’s EU/UK Biotech C-Suite Remuneration & Diversity Study is a data-driven resource that empowers executives, investors and the boardroom with the insights they need to improve board governance, top-level business decisions and truly excel. This strictly independent, anonymised and confidential remuneration study is designed to leverage participation from the entire European and UK biotech ecosystem that will give the very latest data to drive important insights for all decision-makers in the sector.

Released January 2024, PIR International’s EU/UK Biotech C-Suite Remuneration & Diversity Study dissects remuneration, participation, equity level, geographic and diversity representation, in correlation to key metrics such as investment level, founder status and other quantitative and qualitative measures. All aimed to give the latest and actionable insights for company governance in the European and UK biotech sector.

We are currently welcoming participation in this anonymous and independent study from any C-Suite member of a life science or biotechnology organisation in Europe or the UK that is considered a small to medium sized organisation, that may be private or publicly funded, and at any stage of research or commercialisation.